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Group-Based Trajectory Models: Assessing
Adherence to Antihypertensive Medication in
Older Adults in a Community Pharmacy Setting
Paul Dillon1, Derek Stewart2, Susan M. Smith3, Paul Gallagher1 and Grainne Cousins1
Antihypertensive medication nonadherence is highly prevalent, leading to uncontrolled blood pressure. Methods that
facilitate the targeting and tailoring of adherence interventions in clinical settings are required. Group-Based Trajectory
Modeling (GBTM) is a newer method to evaluate adherence using pharmacy dispensing (refill) data that has advantages
over traditional refill adherencemetrics (e.g. Proportion of Days Covered) by identifying groups of patients whomay benefit
from adherence interventions, and identifying patterns of adherence behavior over time that may facilitate tailoring of an
adherence intervention. We evaluated adherence to antihypertensive medication in 905 patients over a 12-month period in
a community pharmacy setting using GBTM, identifying three subgroups of adherence patterns: 52.8%, 40.7%, and 6.5%
had very high, high, and low adherence, respectively. However, GBTM failed to demonstrate predictive validity with blood
pressure at 12months. Further research on the validity of adherencemeasures that facilitate interventions in clinical set-
tings is required.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Antihypertensive medication nonadherence is a major cause
of the failure to achieve blood pressure targets. Numerous
adherence interventions exist; however, they would benefit
from methods in clinical settings that facilitate the targeting
and tailoring of interventions.
WHAT QUESTION DID THIS STUDY ADDRESS?
 GBTM, a newer method to evaluate adherence using phar-
macy refill data which may facilitate the targeting and tailoring
of interventions, was tested for predictive validity with blood
pressure in a community pharmacy setting.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Neither GBTM nor traditional pharmacy refill adherence
methods demonstrated predictive validity in this clinical setting.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Applications embedded within community pharmacy sys-
tems to evaluate patient adherence may facilitate uptake of
interventions into practice; however, further research is needed
to find valid and reliable methods.
Adherence to medication has often been defined as the extent to
which a patient takes their medication as prescribed.1–3 Medica-
tion nonadherence, however, is highly prevalent across chronic
illnesses, estimated at 34–50%,4 leading the World Health
Organization to suggest that increasing medication adherence
may have a greater impact on the health of populations than any
improvement in specific medical treatments.2 Poor adherence to
antihypertensive medication is a key factor in the failure to con-
trol hypertension,5 with the prevalence of optimal adherence
(more than 80% of doses taken) to antihypertensive medication
estimated at 59%, which is associated with a 19% reduced risk of
cardiovascular disease and a 29% reduction in risk of all-cause
mortality.6 Numerous effective interventions to improve adher-
ence to antihypertensive medication and reduce blood pressure
exist, including simplification of dose regimen, reminders, patient
education, motivation, and support.7 Yet few adherence interven-
tions lead to large improvements in adherence and clinical out-
comes, and interventions that improve both adherence and
clinical outcomes tend to be complex, which limits feasibility in
practice.8,9 However, failure to target interventions to nonadher-
ent patients and to tailor the intervention to individual patient
barriers to adherence may have undermined the success of inter-
ventions in clinical settings.7,8 In a recent pragmatic trial of
reminder devices, one potential reason for the absence of
improvements in adherence was the failure to tailor the interven-
tion to patients who may be forgetful.10 Tailoring of complex
interventions may improve effectiveness and also improve feasi-
bility in routine clinical settings.11
Methods to identify patients with poor adherence and to assess
specific barriers to adherence in clinical settings are required to
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facilitate the targeting of complex interventions to appropriate
patients. Pharmacy dispensing (refill) data have been used to esti-
mate patient adherence and is considered suitable for use in clini-
cal settings.12,13 The Medication Possession Ratio (MPR) and
the Proportion of Days Covered (PDC) are the most commonly
derived indices.14,15 These reduce complex longitudinal dispens-
ing data to a single easily understood summary estimate of the
ratio or percentage of medication available to a patient during a
defined period and aid identification of patients who may benefit
from adherence interventions. However, this reduction in com-
plexity results in loss of information, particularly the patterns of
adherence behavior. Medication adherence can be conceptualized
as a dynamic process consisting of three distinct components: ini-
tiation, implementation, and persistence.1 The reduction of com-
plexity with PDC limits the ability to distinguish patients with
considerable differences in their initiation, implementation, and
persistence behaviors, and fails to account for the dynamic nature
of adherence.16 For example, a patient who discontinues medica-
tion halfway through a treatment period will have an identical
PDC to a patient who misses a dose every second day. It has been
suggested that patients who discontinue medication require dif-
ferent interventions to those who have issues with remembering
to take medication each day, for example, remotivation to adhere
vs. reminders to take medication.1
A newer method to measure adherence using pharmacy dis-
pensing records is Group-Based Trajectory Modeling (GBTM).16
The advancement associated with GBTM over PDC is, first, its
ability to identify clusters or groups of patients with similar pat-
terns of pharmacy medication refill behavior, depicting this in an
intuitive graphic,16 which may facilitate the targeting of interven-
tions to patients who may benefit from adherence interventions;
and, second, for each group it defines a trajectory of medication
refill behavior over time, revealing patterns of medication adher-
ence that may facilitate tailoring of interventions.17 Recent stud-
ies have found GBTM to be superior to PDC in evaluating
adherence.18–22 Furthermore, differences in modifiable determi-
nants of adherence between adherence trajectory groupings have
been observed in patients with coronary heart disease18 and heart
failure.20
GBTM appears to be a promising method to identify poor
adherence and to tailor adherence interventions in clinical set-
tings such as community pharmacy. However, to date studies
characterizing adherence using GBTM have been predominantly
retrospective, utilizing claims databases, including only patients
covered by the relevant insurance scheme and those initiating
medication during the observation period. No published studies
exist characterizing antihypertensive medication adherence using
GBTM in older adults attending a community pharmacy and the
validity of this adherence measure in a clinical setting has not
been tested. The objectives of our study were 1) to characterize
adherence to antihypertensive medication in a cohort of older
community-dwelling adults with hypertension using dispensing
data from the community pharmacy, and 2) to test the predictive
validity of GBTM derived from community pharmacy dispensing
data against systolic and diastolic blood pressure.
RESULTS
Participants
A total of 2,231 consecutive patients were invited to participate
from 106 community pharmacies across the Republic of Ireland,
71% (N 5 1,592) consented and completed the baseline tele-
phone interview. Twenty-eight participants were ineligible as
they did not meet the inclusion criteria, leaving a sample of 1,564
at baseline. At 12 months, participants were recontacted, 1,232
(79%) agreeing to the follow-up interview. Each interview was
linked to dispensing records from that pharmacy for the previous
12 months. For those completing follow-up interview, 138
reported not always attending the pharmacy of recruitment and
thus were excluded from adherence assessment, as medication dis-
pensed elsewhere was not captured, while pharmacy dispensing
records were not available for a further 189 participants, leaving a
final sample of 905 (57.9%) participants (Figure 1).
GBTMs
Four trajectory models were generated ranging from 2–5 adher-
ence trajectory groups (Figure 2). Increasing the number of
groups yielded improvements in statistical fit (Bayesian Informa-
tion Criterion (BIC), Akaike Information Criterion (AIC), and
Entropy); however, based on the requirement to have a mini-
mum group size of at least 5%, the three-group model was consid-
ered best fit (Table 1). In this three-group model, three distinct
patterns of medication adherence were apparent during 12-
month follow-up that may be considered as very high levels of
adherence, consistently high levels of adherence, and low levels of
adherence, which decreased slightly during follow-up. Based on
each participants highest group membership probability, 52.8%,
40.7%, and 6.5% were assigned to each group, respectively
Relative to the very high adherence group, participants in the
low and high adherence groups were less likely to be eligible for
the General Medical Services (GMS) scheme, to use fewer regular
medications, to have higher concerns about their medication, and
lower necessity beliefs (assessed using BMQ) (Table 2). Trajec-
tory groups were also significantly associated with PDC and med-
ication gaps. In multivariate multinomial logistic regression
models adjusted for age and gender, GMS eligibility was not asso-
ciated with trajectory grouping; more regular medication was
associated with lower risk of low and high adherence relative to
the very high group; while higher medication necessity beliefs
were associated with a reduced risk of high adherence relative to
the very high group (Table 3).
Blood pressure
Of the 905 participants assigned to adherence trajectory groups,
667 attended for blood pressure measurement. Using standard
blood pressure (>140/90 mmHg) cutpoints, 39% (n 5 261) of
participants had uncontrolled blood pressure (mean systolic/
diastolic blood pressure 135.25/76.80 mm Hg). In adjusted linear
regression analyses, no significant associations between systolic
blood pressure nor diastolic blood pressure and trajectory group-
ings were observed (Table 4). The regular use of dosage forms for-
mulated with high quantities of sodium (e.g., soluble/dispersible
tablets) were associated with significantly higher systolic blood
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pressure and age was inversely associated with diastolic blood pres-
sure. In a sensitivity analysis using PDC and medication gaps, no
significant associations with blood pressure were observed (Table
5). Finally, a secondary analysis, limiting the adherence assessment
period to the final 3 months of follow-up did not alter the
findings.
DISCUSSION
In this prospective cohort study of older adults with hyperten-
sion, a three-group trajectory model best summarized adherence
patterns during 12-month follow-up. The patterns revealed three
groups with a very high level of adherence, a consistently high
level of adherence, and a low level of adherence that decreased
over time. Based on individual participant’s highest group mem-
bership probability, 52.8%, 40.7%, and 6.5% of participants were
assigned to the respective groups, which were significantly associ-
ated with concurrent PDC and medication gaps. In assessing the
effect of adherence on subsequent clinical outcomes, adherence
trajectory groups were not associated with blood pressure. In a
sensitivity analysis, PDC and medication gaps were also not asso-
ciated with blood pressure.
Previous studies have utilized GBTM on pharmacy claims data
to assess adherence to statins,16,21,23 diabetes medication,19 heart
failure medication,20 coronary heart disease medication,18 and
glaucoma medication.22 The number of distinct trajectory groups
identified in these studies ranged from three to seven. For exam-
ple, Librero et al. identified three distinct patterns of statin adher-
ence posthospitalization for acute coronary syndrome that were
labeled always adherent, occasional users, and fast declining.18 In
contrast, Lo-Ciganic et al. identified seven distinct patterns of
oral hypoglycemic adherence in new users, which included four
groups with consistent levels of adherence ranging from low to
perfect and three groups with steep declines in adherence includ-
ing immediate nonadherence, early discontinuation, and late dis-
continuation.19 We observed relatively high levels of adherence,
with more than 90% of participants classified as having higher
than 80% adherence, much higher than the 59% meta-analytical
finding.6 Half the cohort was grouped into a very high adherence
trajectory, while a further 40% were grouped separately into a
consistently high adherence trajectory. Employing an arbitrary
cutoff of 80% would not differentiate the second group, who
clinically may represent a group of patients who occasionally miss
Figure 1 Flowchart of participants through the study.
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doses. Finally, a low proportion of the cohort was classified as
having low adherence, identifying a target group for adherence
interventions.
It is important to note differences in participant characteristics
with previous studies; participants in our study consisted largely
of prevalent users of antihypertensive medication (mean length
of time on antihypertensive medication was 11.5 years) with
2.5% (n 5 36) of the cohort at recruitment taking antihyper-
tensive medication for fewer than 12 months. In comparison,
other studies utilizing GBTM have predominantly studied new-
users of long-term medication. Previous research has shown
50% of patients discontinue antihypertensive medication
within the first 12 months of therapy.24,25 Furthermore, the
meta-analytical findings included an upper 95% confidence inter-
val of 77%, and an upper range of 93%, with adherence rates
varying by study design, adherence measure, and medication type,
but also factors such as age.6 The high levels of adherence and the
absence of steep declining adherence patterns observed in our
study is likely attributable to the cohort characteristics, which
may represent a population at low risk of poor adherence.
Previous studies assessing associations between baseline charac-
teristics and trajectory groups have identified factors such as age,
education, race, and medication copayments to significantly
affect adherence trajectory group membership.18,20,22 Modifiable
Table 1 Model fit statistics
Model BIC (N5 10586) BIC (N5 895) AIC >5% per group Entropy
2 Groups –14202.08 –14192.18 –14172.95 Yes Yes
3 Groups –13930.57 –13916.96 –13890.52 Yes Yes
4 Groups –13829.83 –13810.02 –13771.56 No Yes
5 Groups –13778.71 –13753.96 –13705.88 No Yes
BIC, Bayesian Information Criterion; AIC, Akaike Information Criterion. Each model yielded improvements in model fit statistics however for models with more than 3 groups
the smallest group consisted of less than 5% of study sample.
Figure 2 Trajectory Group Models with 2–5 groups. In each plot the solid lines represent the estimated adherence trajectories and the dot symbols rep-
resent the group means at each interval. Percentages of estimated group membership probabilities are presented alongside the description of the esti-
mated adherence trajectory. These represent the mean estimated probability of membership to each group. The estimated group percentage differs from
the adherence group membership, which is a categorical variable following assignment of participants to their most likely group. The x-axis represents
each 30-day interval during the follow-up period, while the y-axis represents the number of days covered with an antihypertensive medication within each
30-day interval.
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determinants of adherence that are significantly associated with
low adherence groups could be used to tailor appropriate adher-
ence interventions. We identified that taking more regular medi-
cation was associated with the very high adherence group. The
effect of the number of medication on adherence is mixed, with
observational studies reporting conflicting findings.26 Patients
who take more medication may find it difficult to adhere to a
complex regimen, while on the other hand these patients may
have stronger medication-taking habits. The contradictory find-
ings may also relate to variations in definitions for polypharmacy,
but also it is important to consider methods to evaluate adher-
ence to multiple related medications. In our modeling we utilized
a strategy proposed by Choudhury et al.27 We also observed
patients with lower necessity beliefs were less likely to be in the
very high adherence group, and similarly that higher medication
concerns may also be associated with lower adherence groupings.
These are consistent with previous findings that stronger neces-
sity beliefs and lower concerns are associated with better adher-
ence.28 However, it must be noted that it is recommended to
assess the multidimensional relationship of patient medication
concerns and necessity beliefs with adherence using a continuous
measure of adherence and to utilize polynomial regression to test
the multidimensional relationship.29 Assessing medication beliefs
of patients with adherence issues identified by GBTM may fur-
ther facilitate the tailoring of adherence interventions, e.g.,
motivational-based interventions.8,9 This analysis further highlights
Table 2 Baseline characteristics by adherence trajectory grouping
Total cohort
N 5 905
Low
n5 59
(6.5%)
High
n5 368 (40.7%)
Very high
n5 478 (52.8%) P-value
Age 76.39 75.49 76.04 76.76 0.127
Male Gender 47.1% (426) 49.2% (29) 51.4% (189) 43.5% (208) 0.073
Education
Secondary 42.8% (369) 34.6% (19) 40.4% (140) 45.6% (210)
Third Level 27.6% (238) 34.6% (19) 30.0% (104) 25.0% (115) 0.281
GMS Patient 74.6% (662) 63.8% (37) 71.5% (258) 78.3% (367 0.013
Current Smoker 7.8% (70) 12.1% (7) 7.9% (29) 7.2% (34) 0.416
Heart Attack 14.9% (134) 11.9% (7) 14.2% (52) 15.7% (75) 0.663
Angina 14.0% (126) 8.5% (5) 15.0% (55) 13.8% (66) 0.400
Stroke 3.8% (34) 5.1% (3) 2.7% (10) 4.4% (21) 0.388
Comorbidities (mean no.) 2.41 2.24 2.34 2.49 0.289
Time on AHT meds (mean years) 11.45 8.84 11.26 11.89 0.069
Unique medication (mean no.) 6.52 4.16 6.32 6.97 <0.001
MDS Repackaging 11.3% (102) 8.5% (5) 11.7% (43) 11.3% (54) 0.769
AHT medication (mean no.) 1.98 1.94 1.97 2.00 0.900
Dose Frequency 1.11 1.14 1.11 1.10 0.702
Defined Daily Dose (mean WHO-DDD) 2.62 2.80 2.60 2.62 0.821
ACEIs/ARBs 76.6% (684) 72.4% (42) 77.1% (280) 76.7% (362) 0.731
Alpha-blockers 6.5% (58) 6.9% (4) 7.2% (26) 5.9% (28) 0.768
Beta-blockers 50.2% (448) 48.3% (28) 48.5% (176) 51.7% (244) 0.627
CCBs 43.9% (392) 41.4% (24) 45.2% (164) 43.2% (204) 0.787
Diuretics 29.0% (259) 27.6% (16) 27.8% (101) 30.1% (142) 0.752
BMQ-Specific Concerns (mean score) 2.18 2.33 2.19 2.13 0.044
BMQ-Specific Necessity (mean score) 3.65 3.5 3.61 3.77 0.003
PDC (mean) 0.94 0.69 0.92 0.98 <0.001
Medication Gaps (mean no.) 1.67 4.05 2.30 0.89 <0.001
GMS, General Medical Services; AHT, Antihypertensive; MDS, Multidose Compartment Systems; WHO-DDD, World Health Organisation Defined Daily Dose; ACEIs, Angio-
tensin Converting Enzyme Inhibitors; ARBs, Angiotensin Receptor Blockers; CCBs, Calcium Channel Blockers; BMQ, Beliefs about Medication Questionaire; PDC, Propor-
tion of Days Covered. Chi-square to test categorical variables; Analysis of Variance to test continuous variables. Higher scores on the BMQ-Concerns indicate greater
concerns regarding antihypertensive medication; higher scores on the BMQ-Necessity indicate stronger beliefs in the necessity of antihypertensive medication.
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important clinical differences between the two high adherence
groups; however, it is limited by the low number of participants in
the smallest group, precluding the inclusion of all theoretically rele-
vant variables in the final multivariate model.
Adherence trajectory groups have been shown to predict clini-
cal outcomes in users of statins and oral hypoglycaemics19,21;
however, we did not observe significant associations between tra-
jectory groups and blood pressure. In a sensitivity analysis neither
PDC nor medication gaps were associated with blood pressure. A
number of reasons may explain this observation. First, in cohorts
of prevalent antihypertensive medication users with relatively
high levels of adherence, other factors influencing blood pressure
may be responsible for the variance.30 Previous studies of cohorts
with established hypertension recruited from primary-care set-
tings similarly observed high levels of adherence and the absence
of a relationship with subsequent blood pressure.31 For popula-
tions with high levels of adherence, factors such as nonresponse
to treatment may be responsible for inadequate blood pressure
control. In our multivariable models, neither the combined dose
of all antihypertensive medication nor class of medication was
associated with blood pressure. We did observe, however, that
patients who were regularly dispensed high sodium dosage forms
(predominantly soluble analgesics) had significantly higher sys-
tolic blood pressure. High-salt intake is associated with higher
blood pressure,32 and a previous large-scale observational study
reported that patients receiving high sodium medicines, predomi-
nantly effervescent, dispersible, and soluble formulations, had a
significantly increased risk of cardiovascular events compared to
patients receiving equivalent nonsodium-containing medica-
tion.33 The majority of high sodium dosage forms identified in
our cohort have alternative, nonsoluble, low-sodium formulations
that should be supplied preferentially to hypertensive patients.
Another possible explanation for the absence of a relationship
between adherence and blood pressure in this study may relate to
“white-coat adherence,” whereby a patient increases adherence in
the days prior to a clinic visit or measurement being taken.34,35 It
is possible that following invitation to attend for blood pressure
measurement, participants altered their adherence behavior. Simi-
lar to the effects of white coat adherence, adherence behavior
immediately prior to measuring blood pressure is likely to influ-
ence blood pressure to a greater extent. However, a secondary
analysis utilizing refill adherence estimates generated for the 3
months immediately prior to BP measurement did not alter the
findings.
The findings of this study should be interpreted in the light of
its limitations. First, we measured blood pressure at a single time-
point in a clinic setting, which is less reliable than methods such
as 24-hour ambulatory monitoring or measurements taken at
home. However, this is a still a valid method employed by large-
scale longitudinal studies36 and recommended by clinical guide-
lines, e.g., NICE, ESH. Second, a limitation to the construct
validity of pharmacy refill measures is the assumption that medi-
cation dispensed to a patient is consumed, and that the medica-
tion is consumed at a rate equivalent to which it is dispensed.15 It
is possible that this assumption has undermined the validity of
the pharmacy adherence measurements. Finally, attrition was
higher for participants with lower PDC at baseline; however, this
was not evident for other adherence measurements at baseline,
including trajectory group and medication gaps, and thus is
unlikely to have biased the results.
Valid and reliable methods to identify poor adherence and to
facilitate tailoring of interventions in clinical settings are
needed.12,13 Applications integrated into pharmacy dispensing
systems may aid clinicians to identify subgroups of patients with
medication adherence issues. GBTM is a newer method to evalu-
ate adherence using pharmacy-dispensing data that has been
attributed advantages over traditional measures such as PDC16;
however, in our study GBTM when applied to pharmacy dispens-
ing records to evaluate antihypertensive medication adherence
failed to demonstrate predictive validity with blood pressure.
Although concordance was observed with other adherence mea-
sures, it is likely that the various adherence measures evaluate dif-
ferent aspects of medication adherence behavior, thus limiting
conclusions drawn from concurrent assessments. Further research
to identify suitably valid adherence refill measures in a commu-
nity pharmacy setting is required.
METHODS
Study design and setting
We conducted a prospective cohort study, recruiting participants from
106 community pharmacies across the Republic of Ireland between
March and May 2014. Pharmacies were selected on the basis of partici-
pating in the National Pharmacy Internship Programme. Consecutive
participants were invited to take part if they met the following inclusion
criteria: presenting to a participating pharmacy to fill a prescription for
at least one medication for hypertension as determined by the pharma-
cist, aged 65 years or older, community dwelling, able to speak and
Table 3 Multivariate multinomial logistic regression (n 5 824)
RRR 95% CI P-value
Group 1 - Low
Age 0.99 0.93-1.05 0.687
Male Gender 1.26 0.72-2.19 0.412
GMS Patient 0.89 0.46-1.71 0.719
No. of unique medication 0.77 0.65-0.90 0.002
BMQ Concerns 1.66 0.97-2.84 0.065
BMQ Necessity 0.72 0.47-1.08 0.114
Group 2 - High
Age 0.99 0.97-1.02 0.536
Male Gender 1.23 0.89-1.70 0.201
GMS Patient 0.79 0.56-1.11 0.179
No. of unique medication 0.96 0.92-0.99 0.025
BMQ Concerns 1.27 0.97-1.66 0.088
BMQ Necessity 0.73 0.60-0.89 0.002
Final model (n5 824) due to missing data; age (5), GMS Patient (17), no. of
unique medication (12); BMQ concerns (31), BMQ necessity (21). GMS, General
Medical Services; BMQ, Beliefs about Medication Questionnaire. Standard errors
adjusted for 87 clusters.
ARTICLE
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 103 NUMBER 6 | JUNE 2018 1057
understand English, and no evidence of cognitive impairment. After
obtaining informed consent, participants completed a structured tele-
phone interview conducted by trained pharmacy interns and were recon-
tacted at 12 months to complete a follow-up structured telephone
interview. At follow-up participants were invited to attend the pharmacy
to have their blood pressure measured. Medication adherence during
follow-up was characterized using GBTM and associations between base-
line patient characteristics and trajectory groups were assessed in multi-
variate regression models. The predictive validity of GBTM was tested
through significant associations with blood pressure. A sensitivity analy-
sis using traditional adherence refill metrics (PDC and medication gaps)
was also undertaken.
Ethical approval for this study was granted by the Research Ethics
Committee of the Royal College of Surgeons in Ireland.
Study variables
Group-based trajectory modeling. GBTM is an application of finite
mixture modeling that allows identification of groups of individuals with
a similar evolution of an outcome over time, such as medication adher-
ence, through maximum likelihood estimation. For an in-depth technical
discussion of GBTM, please refer to Nagin and Tremblay (2001), and
for an overview, refer to Nagin (2014).37,38 GBTM was applied to phar-
macy medication dispensing records for the 12-month follow-up period,
which included information on the date of the dispensing, the product
and quantity dispensed, and directions for use. A medication supply
diary was created for each participant divided into 12 30-day intervals
that recorded the number of days within each interval for which antihy-
pertensive medication was theoretically available to the patient based on
the date and quantity of consecutive antihypertensive medication refills.
Table 4 Linear regression model of antihypertensive medication adherence trajectory group and systolic/diastolic blood pressure
adjusted for covariates
Systolic blood pressure Diastolic blood pressure
b (95% CI) p b (95% CI) P
Trajectory Group
Low 20.93 (26.60 to 4.75) 0.746 0.62 (23.13 to 4.36) 0.743
High 21.94 (24.48 to 0.60) 0.132 21.29 (23.09 to 0.50) 0.155
Very High Ref 2 Ref 2
Male 2.08 (20.82 to 4.99) 0.157 20.20 (21.97 to 1.56) 0.820
Age 0.05 (20.17 to 0.28) 0.627 20.19 (20.35 to20.03) 0.020
Smoker 0.22 (25.14 to 5.60) 0.934 20.70 (23.78 to 2.43) 0.669
Private Health Insurance 1.28 (22.18 to 4.75) 0.463 20.30 (22.53 to 1.92) 0.788
GMS Patient 22.26 (25.64 to 1.12) 0.186 21.01 (23.28 to 1.26) 0.380
High Sodium Dosage Forms 9.41 (2.15 to 16.68) 0.012 0.49 (24.03 to 5.00) 0.831
Defined Daily Dose (WHO-DDD) 0.37 (20.69 to 1.42) 0.489 20.23 (21.07 to 0.50) 0.594
ACEIs/ARBs 0.04 (23.20 to 3.28) 0.979 21.78 (24.06 to 0.50) 0.124
Alpha-blocker 0.43 (25.89 to 6.74) 0.893 0.06 (24.90 to 5.00) 0.982
Beta-blocker 2.25 (20.89 to 5.39) 0.158 20.64 (22.30 to 1.03) 0.449
Diuretics 2.81 (20.24 to 5.87) 0.071 0.07 (22.11 to 2.25) 0.949
CCBs 3.38 (20.30 to 7.04) 0.071 20.32 (22.61 to 1.97) 0.781
Previous CVE 21.98 (25.06 to 1.10) 0.204 20.57 (22.52 to 1.38) 0.560
Diabetes 20.59 (24.24 to 3.06) 0.749 0.52 (22.76 to 1.73) 0.651
Renal Disease 1.88 (26.15 to 9.91) 0.642 21.02 (28.17 to 6.14) 0.778
Final model (n5 644) due to missing data; age (3), smoker (3), private health insurance (7), medical card holder (6), and antihypertensive medication strength (9). GMS,
General Medical Services; WHO-DDD, World Health Organization Defined Daily Dose; ACEIs, Angiotensin Converting Enzyme Inhibitors; ARBs, Angiotensin Receptor Block-
ers; CCBs, Calcium Channel Blockers; CVE, cardiovascular events. Standard errors adjusted for 73 clusters.
Table 5 Separate linear regression models of adherence measures (PDC and medication gaps) and systolic/diastolic blood pressure
adjusted for covariates
Systolic blood pressure Diastolic blood pressure
b (95% CI) p b (95% CI) P
PDC 5.81 (25.44 to 17.05) 0.307 1.47 (25.86 to 8.80) 0.690
Medication Gaps 20.25 (20.89 to 0.38) 0.429 0.13 (20.31 to 0.57) 0.569
Final model (n 5 644) adjusted for gender, age, smoking status, private health insurance, General Medical Services eligibility, use of high sodium dosage forms, antihyper-
tensive dose, antihypertensive class, previous cardiovascular event, diabetes and kidney disease. PDC, Proportion of Days Covered. Standard errors adjusted for 73 clus-
ters using Sandwich-Estimator.
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For patients taking multiple antihypertensive medications, an average of
the days’ supplies for all antihypertensive medication was taken. When
further medication was dispensed prior to exhausting a previous supply,
the new supply was considered to begin after the previous supply was
exhausted, to a maximum excess of 180 days of medication. The cen-
sored normal distribution was used to analyze the adherence data. Tra-
jectory models with 2–5 groups were generated and for each model the
polynomial function of time that best fits the data was selected. The out-
put of GBTM includes estimated probabilities of group membership for
each individual and each trajectory group, a categorical variable denoting
the assigned group for each individual based on the highest estimated
probability and a trajectory curve for each group over time. BIC, AIC,
and Entropy were used to guide final model selection. To ensure model
adequacy and usefulness, a minimum of 5% of participants were required
to be assigned to each trajectory grouping.38,39
Proportion of days covered. The proportion of days covered (PDC) is a
common refill measure,15 and its validity in hypertension has been demon-
strated through significant associations with blood pressure control.40–42
The PDC was calculated by dividing the number of days’ covered by the
antihypertensive medication from the date of the first prescription during
the observation period to the end of the observation period. Oversupplies
at the end of the observation period were excluded. For patients receiving
multiple antihypertensive medication, an overall PDC was obtained by
averaging PDCs across each class of antihypertensive. PDCs exceeding 1,
which indicate oversupplies of medication, were recoded to 1.
Medication gaps. A potential weakness associated with GBTM is the
inability to account for short periods of nonpersistence that may have
significant clinical outcomes. For example, short periods of nonadher-
ence to oral contraceptives or antiretroviral medication may lead to
unplanned pregnancy or failure to maintain viral suppression.43 Thus,
we also estimated the number of occasions that gaps of 5 days occurred
between each medication supply during the 12-month follow-up. If fur-
ther medication was obtained prior to exhausting a previous supply, the
new supply was considered to begin after the previous supply was
exhausted, to a maximum excess of 180 days of medication.
Blood pressure. Systolic blood pressure and diastolic blood pressure
were measured at 12-month follow-up. A standardized study protocol
was used, based on the The Irish Longitudinal Study of Ageing (TILDA)
protocol for BP measurement (two measurements while seated with
elbow supported, taken 2 min apart) using study blood pressure moni-
tors (Omron M6 Comfort BP monitor; Hoofddorp, Netherlands).36
Training was provided to pharmacy interns to measure blood pressure,
while pharmacists were provided with the study monitor and protocol.
The average of two blood pressure readings was calculated.
Covariates. To assess the association between patient characteristics
and trajectory groups, factors previously identified to influence adherence
including demographics (i.e., age, gender, education, and state-funded
healthcare status), beliefs about medicines, health behaviors (smoking),
comorbidities, and medication history were recorded at the baseline
interview.2 Eligibility for the Irish General Medical Scheme (GMS) is by
means-testing based on income and is a socioeconomic indicator. The
concerns and necessity-beliefs subscales of the Beliefs about Medicines
Questionnaire (BMQ-Specific) were administered at baseline. According
to the Necessity-Concerns Framework (NCF), patients are more likely
to take their medication if they have stronger medication necessity beliefs
and fewer medication concerns. The subscales of the BMQ-Specific con-
sists of five items measuring concerns about medication (e.g., “Having to
take medicines worries me”) and five items regarding patients necessity-
beliefs about medication (e.g., “My health, at present, depends on my
medicine”), on a 5-point Likert scale, which was rated with regard to
antihypertensive.44 Higher scores on the BMQ-Concerns indicate
greater concerns regarding antihypertensive medication; higher scores on
the BMQ-Necessity indicate stronger beliefs for the necessity of antihy-
pertensive medication. Multimorbidity was measured as a count of self-
reported comorbid conditions.45 History of heart attack, angina, and
stroke were considered important covariates, as adherence to treatment
of hypertension for secondary prevention may be higher.46 The use of
multidose units packaging (MDUs), the number of regular medicines,
the class and number of specific antihypertensive medication, and the
dosing frequency, which may also influence adherence,47–49 were deter-
mined at baseline from dispensing records.
To control for confounding in linear regression models predicting
blood pressure, a number of covariates recorded during the follow-up
interview were considered for inclusion in multivariable models due to
theoretical associations with blood pressure including age, gender, smok-
ing status, medical history, and medication use. An additional variable
identified from pharmacy records was the regular use of high sodium-
content dosage forms (e.g., soluble analgesics). Soluble dosage forms con-
tain high levels of sodium, which often exceed the recommend daily
sodium allowances and may contribute to higher blood pressure.
Statistical analyses
Characteristics of the sample are described overall and by trajectory
grouping of the final GBTM model. Associations between participant
characteristics and trajectory group were assessed using appropriate tests
(e.g., chi-square). Multivariate multinomial logistic regression was used
to assess differences in baseline characteristics across adherence trajectory
groups, with the number of variables included limited by the size of the
smallest trajectory group. The predictive validity of adherence trajectory
groups were assessed by examining associations with systolic and diastolic
blood pressure in linear regression models adjusted for covariates. In sen-
sitivity analyses, PDC and medication gaps were also assessed for associa-
tions with blood pressure. Furthermore, a secondary analysis using
adherence estimates for the final 3-month period of follow-up was
undertaken, as medication-taking behavior during a shorter period prior
to blood pressure measurement may be more appropriate than medica-
tion behavior assessed over a 12-month period. Standard errors were
adjusted in regression models using the Sandwich-estimator, due to
potential for dependency of observations at the pharmacy level. Statisti-
cal modeling was performed using Stata v. 13 (StataCorp, College Sta-
tion, TX) and the user-written TRAJ procedure for trajectory models
(www.andrew.cmu.edu/user/bjones).50
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